Powell Investment Advisors LLC Buys Shares of 130,297 Apollomics, Inc. (NASDAQ:APLM)

Powell Investment Advisors LLC bought a new stake in shares of Apollomics, Inc. (NASDAQ:APLM) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned 0.15% of Apollomics at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their price target on shares of Apollomics from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th.

Apollomics Stock Performance

Shares of Apollomics stock traded up $0.00 on Friday, hitting $0.21. 150,771 shares of the company traded hands, compared to its average volume of 312,851. The stock’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.59. Apollomics, Inc. has a 52 week low of $0.18 and a 52 week high of $6.20.

Apollomics Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.